Clinical Trials Logo

Helicobacter Pylori clinical trials

View clinical trials related to Helicobacter Pylori.

Filter by:

NCT ID: NCT05790525 Recruiting - Helicobacter Pylori Clinical Trials

Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy

Start date: November 22, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to assess the effect of oral Helicobacter pylori infection on the efficacy of gastric Helicobacter pylori infection eradication. Patients diagnosed with gastric Helicobacter pylori infection are tested for oral Helicobacter pylori and given standard bismuth quadruple therapy, with a urea breath test, a rapid urease test, or a Helicobacter pylori stool antigen test to confirm gastric Helicobacter pylori eradication at week 6 follow-up, and an oral Helicobacter pylori test kit to confirm oral Helicobacter pylori eradication.

NCT ID: NCT05790512 Completed - Helicobacter Pylori Clinical Trials

Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection

Start date: November 22, 2022
Phase:
Study type: Observational

The aim of this study was to investigate the association between oral Helicobacter pylori infection and gastric Helicobacter pylori infection. Patients who were tested for gastric Helicobacter pylori were tested for oral Helicobacter pylori at the same time, and were divided into four groups according to the test results to compare the positive rate of oral Helicobacter pylori.

NCT ID: NCT05649709 Not yet recruiting - Helicobacter Pylori Clinical Trials

Helicobacter Pylori and Vonoprazan Dual Therapy

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., <90%) when given as first-line treatment for H. pylori infection. This study evaluated the efficacy and safety of low-and high-dose amoxicillin-vonoprazan dual therapy for 14 days as first-line treatment for H. pylori in China.

NCT ID: NCT05635942 Completed - Helicobacter Pylori Clinical Trials

Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication

Helicomatri
Start date: January 29, 2019
Phase: Phase 4
Study type: Interventional

The goal of this prospective randomized clinical trial is to compare the rate of Helicobacter Pylori (HP) eradication after standard or dose-optimized amoxicillin quadritherapy in patients naïve to any anti-HP treatment and with chronic HP infection documented by histological examination. The main questions it aims to answer are: - compare the eradication rate of H.Pylori after a standard concomitant quadritherapy with 2g of amoxicillin versus an optimized quadritherapy with 3g of amoxicillin, in Tunisian population - Identify different factors associated with poor therapeutic response Patients were randomly assigned to either standard quadruple therapy (Qs-14: amoxicillin 1g twice daily, clarithromycin 500mg twice daily, metronidazole 500mg twice daily and esomeprazole 40mg twice daily for 14 days), or optimized quadruple therapy (Qo-14: amoxicillin 1g three times a day, clarithromycin 500mg twice daily, metronidazole 500mg twice daily and esomeprazole 40mg twice daily for 14 days). Eradication control was performed by urea breath test.

NCT ID: NCT05449028 Recruiting - Gut Microbiota Clinical Trials

Helicobacter Pylori Eradication Therapy in Portugal

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Helicobacter pylori (H. pylori) infection remains a major public health problem, with an estimated prevalence of over 50% worldwide and 60-86% for Portugal. H. pylori is associated with significant morbidity and mortality from peptic ulcerative disease to gastric cancer, whose eradication therapy has proven to be effective in preventing these complications. Factors involved in the development of these conditions include H. pylori virulence, host genetic factors and gut microbiota. Given the increasing pattern of antibiotic resistance evidenced by this bacterium and the scarcity of available antibiotic therapy, both in Portugal and worldwide, there is not enough evidence on the best eradication strategy. Regarding the uncertainties about the potential negative impact of indiscriminate use of eradication therapy on gut microbiota, either by proton pump inhibitors or by antibiotics per se, there is an overriding need for evidence about the real impact of this therapy on oral or gut flora and possible clinical consequences in immunological, metabolic, nutritional and oncological terms. Objectives: Comparative evaluation of the efficacy of the different quadruple therapy regimens recommended for the H. pylori eradication. Comparative evaluation of the safety profile in terms of clinical, and immunological and gut microbiota impact of the different therapies for the H. pylori eradication.

NCT ID: NCT05371249 Active, not recruiting - Helicobacter Pylori Clinical Trials

Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy

Start date: December 1, 2021
Phase: Phase 4
Study type: Interventional

This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a randomized controlled trial.

NCT ID: NCT05345210 Recruiting - Helicobacter Pylori Clinical Trials

Vonoprazan Hp Dual or Triple Eradication Regimes

Start date: April 25, 2022
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of dual or triple regimes for Helicobacter Pylori eradication using Vonoprazan as the antiacid agent.

NCT ID: NCT05276557 Recruiting - Safety Clinical Trials

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

Start date: November 17, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample. Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System. Treating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician. Total duration of study is anticipated to be approximately 6 months.

NCT ID: NCT05184491 Recruiting - Helicobacter Pylori Clinical Trials

Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management

NILE
Start date: October 15, 2021
Phase: Phase 4
Study type: Interventional

The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients who failed previous therapies.

NCT ID: NCT05073367 Completed - Helicobacter Pylori Clinical Trials

A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China

Start date: September 21, 2022
Phase:
Study type: Observational

The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China. In this study, the study doctors will review medical records of participants who have had H. pylori infections any time from 1st January 2019 to 31st December 2021. This study is about collecting existing data only; participants are not treated and do not need to visit a study doctor during this study.